(Boston, MA): The Neuroendocrine Tumor Research Foundation (NETRF) is proud to join Chimeric Therapeutics in announcing that CAR T-cell therapy using CHM CDH17 has been granted Fast Track Designation by the US Food and Drug Administration. This designation recognizes the potential of this new treatment to address the unmet need for additional therapies for GEP-NETs.  … Continue reading CAR T-Cell Therapy for Neuroendocrine Cancer, Now in Clinical Trial, Receives FDA FAST TRACK Designation